Abstract
During COVID-19, while many drugs from conventional medicine (CM) were falling short, those from Ayurveda, Siddha, Herbal Medicine, and Traditional Chinese Medicine (TCM) showed promising potential. The published recovery-aimed clinical studies on medicines from above-mentioned systems were retrieved. For CM, meta-analyses of studies using ICMR-protocol drugs, viz. hydroxychloroquine, azithromycin, favipiravir, ivermectin & remdesivir were searched. For other systems, preferably active-controlled, stand-alone studies, were considered. Their general characteristics, efficacy and safety outcomes were documented. The outcomes were evaluated on basis of a methodology inspired from ‘WHO-Minimal common outcome measure set for COVID-19 clinical research’. The CM drugs were utilized either in multiple combinations or independently. Most studied combination was HCQ and azithromycin. HCQ efficacy was studied in biggest sample. These drugs did not exhibit significant efficacy for early clinical recovery and viral clearance. The adverse event (AE) incidences were also prominent. Barring TCM, studies using Ayurveda regime Tab. Immunofree and Cap. Regimmune and CVO+C, were done in only symptomatic patients. The efficacy of Tab. Immunofree- Cap. Regimmune regime was better than conventional care including azithromycin and favipiravir. The AE incidences in these studies were minimal. Medicines from alternative systems except CM exhibited better efficacy and safety in all outcome measures.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.